Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite-A phase II study from the Swedish Lung Cancer Study Group

Lung Cancer

Volumn 71, Issue 2, 2011, Pages 166-172

  Hallqvist, A ^a   Wagenius, G ^b,c   Rylander, H ^a   Brodin, O ^c   Holmberg, E ^a   Loden B ^d   Ewers, S B ^e   Bergstrom S ^f   Wichardt Johansson, G ^c   Nilsson, K ^b   Ekberg, L ^e   Sederholm, C ^g   Nyman, J ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f GÄVLE HOSPITAL   (Sweden)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cetuximab; Cisplatin; Concurrent radiation; Docetaxel; Induction chemotherapy; Locally advanced; Non small cell lung cancer

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DISTANT METASTASIS; DRUG HYPERSENSITIVITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HISTOPATHOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; LUNG ADENOCARCINOMA; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; SCORING SYSTEM; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE; QUALITY OF LIFE; RECURRENCE; SURVIVAL ANALYSIS; SWEDEN; TAXOIDS; TREATMENT OUTCOME;

EID: 78650937825     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.05.011     Document Type: Article

References (39)

1. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311:899-909.
2. Pritchard R.S., Anthony S.P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996, 125:723-729.
3. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
4. Rowell N.P., O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004, [CD002140].
5. Blackstock A.W., Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 2007, 25:4146-4152.
6. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
7. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
8. Fontanini G., De Laurentiis M., Vignati S., Chine S., Lucchi M., Silvestri V., et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998, 4:241-249.
9. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997, 3:515-522.
10. Ritter C.A., Arteaga C.L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003, 30:3-11.
11. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000, 6:747-753.
12. Lynch T.J., Lilenbaum R., Bonomi P., et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer. Proc Am Soc Clin Oncol 2004, 23:634a.
13. Kim E.S., Mauer A., Tran H., et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc Am Soc Clin Oncol 2003, 22:642a.
14. Rosell R., Robinet G., Ramlau R., et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004, 23:618a.
15. Robert F., Blumenschein K., Dicke T., et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003, 22:643a.
16. Kelly K., Hanna N., Rosenberg A., et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003, 22:644a.
17. Rosell R., Robinet G., Szczesna A., Ramlau R., Constenla M., Mennecier B.C., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19:362-369.
18. Kim E.S., Mauer A.M., William W.N., Tran H.T., Liu D., Lee J.J., et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009, 115:1713-1722.
19. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
20. Raben D., Helfrich B., Chan D.C., Ciardiello F., Zhao L., Franklin W., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005, 11:795-805.
21. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:3852-3859.
22. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
23. Nyman J., Mercke C. Accelerated radiotherapy with docetaxel and cisplatin as induction and concomitant chemotherapy for stage III non-small cell lung cancer. Lung Cancer 2000, 29(Suppl. 1):98.
24. Nyman J., Friesland S., Hallqvist A., Seke M., Bergstrom S., Thaning L., et al. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer 2009, 65:62-67.
25. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
26. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994, 30A:635-642.
27. Blumenschein G., PRWJC R., Robert F., Fossella F.V., Werner-Wasik M., Doescher P., et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol 2008, 26.
28. Govindan R., Bogart J., Wang X., Hodgson L., Kratzke R., Vokes E.E. Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Thorac Oncol 2009, 4(Suppl. 1):9. [Sep updated information presented at the ASCO meeting 2009].
29. Hughes S., Liong J., Miah A., Ahmad S., Leslie M., Harper P., et al. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 2008, 3:648-651.
30. Govindan R., Bogart J., Vokes E.E. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008, 3:917-928.
31. Reymen B. Individualized radiation dose escalation for stage I-III non-small cell lung cancer (NSCLC) based on normal tissue constraints: mature results of a phase II trial 2009, IASCL, San Francisco.
32. Schild S. Survival of patients treated with high-dose radiotherapy & concurrent chemotherapy for unresectable nonsmall cell lung cancer 2009, IASCL, San Francisco.
33. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.
34. Lee J., Ignacio J., Yu C., et al. FAST-ACT: a phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26:431s.
35. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26:2450-2456.
36. Choy H. Initial primary analysis of phase II for RTOG 0117: a phase I/II dose intensification study using three dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable, non-small cell lung cancer (NSCLC) 2009, IASCL, San Francisco.
37. Socinski M.A., Blackstock A.W., Bogart J.A., Wang X., Munley M., Rosenman J., et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008, 26:2457-2463.
38. Stupp R., Mayer M., Kann R., Weder W., Zouhair A., Betticher D.C., et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol 2009, 10:785-793.
39. Saif M.W., Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 2009, 7. 45-53, 64.